Systems, methods, and computer-readable media for enabling ultraviolet radiation treatments are provided.

Photobiomodulation can be used to treat disorders of the gastrointestinal system. The photobiomodulation can be delivered by an intraluminal device (which can be within the gastrointestinal system) that includes at least one light delivery device configured to provide photobiomodulation; at least one photodetector device to measure reflectance based on the photobiomodulation; a processor to receive a reflectance signal from the at least one photodetector device based on the reflectance measured by the at least one photodetector device and process the reflectance signal; and a wireless transceiver coupled to the processor to transmit at least a portion of the processed reflectance signal. The wireless transceiver can communicate with an external device that includes a wireless transceiver to receive the at least the portion of the processed reflectance signal.

An unattended approach can increase the reproducibility and safety of the treatment as the chance of over/under treating of a certain area is significantly decreased. On the other hand, unattended treatment of uneven or rugged areas can be challenging in terms of maintaining proper distance or contact with the treated tissue, mostly on areas which tend to differ from patient to patient (e.g. facial area). Delivering energy via a system of active elements embedded in a flexible pad adhesively attached to the skin offers a possible solution. The unattended approach may include delivering of multiple energies to enhance a visual appearance.

Devices, systems, and methods can be used to deliver photobiomodulation therapy (PBMT) to the GI tract. For example, this document describes battery-enabled LED light source devices that can be deployed through or over an endoscope and anchored directly to the GI tract. Significant systemic effects can be produced by PBMT with application to one part of the body promoting beneficial anti-inflammatory and metabolic benefits in other remote sites promoted by enhanced mitochondrial function and mitokine signaling.

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., skin cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma or basal cell carcinoma.

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., skin cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma or basal cell carcinoma.

A treatment method is disclosed capable of reducing the burden on a patient and enhancing the effect of killing tumor cells. The method includes administering an antibody-photosensitive substance into a vein; inserting an endoscope from a mouth, a nose, or an anus and bringing the endoscope to a vicinity of a tumor after the administering of the antibody-photosensitive substance into the vein; placing an optical fiber into the tumor or in the vicinity of the tumor; irradiating at least one of the tumor, the vicinity of the tumor, or a regional lymph node with a first near-infrared ray by the optical fiber; and irradiating the antibody-photosensitive substance bound to a tumor cell membrane in the tumor cell with a second near-infrared ray after the irradiating with the first near-infrared ray, the second near-infrared ray having a shorter wavelength than that of the first near-infrared ray.

A device for providing fractional treatment of a body orifice includes a source of fractionated energy and a source of electrical muscle (EMS) energy. A programmed controller controls the application of fractionated and/or EMS energy. A probe is inserted by its distal end into the body orifice. The source of fractionated energy is positioned for transmitting fractionated energy from the source of fractionated energy through the probe to tissue in the vicinity around the body orifice; and, the source of EMS is positioned for transmitting EMS energy from the source of EMS energy through the probe to tissue in the vicinity around the body orifice. The programmed controller is configured to control the activation of fractionated energy and EMS energy one of simultaneously or sequentially.

A UV light delivery device for performing intra-corporeal ultraviolet therapy is provided. The device includes an elongated body separated by a proximal end and a distal end. The device also includes a UV light source configured to be received at the receiving space. In some examples, the UV light source is configured to emit light with wavelengths with significant intensity between 320 nm and 410 nm and is utilized in conjunction with an endotracheal tube or a nasopharyngeal airway.

Systems, methods, and computer-readable media for enabling ultraviolet radiation treatments are provided.